On November 18, Recursion Pharmaceuticals, Inc. rose 5.14% in After-Hours Trading, trading at $2.85 per share, with turnover of $1.1708 million.
The key catalyst cited in recent market updates is continued investor focus on the timing of REC-4881’s registrational trial and the scope for valuation recovery following updated clinical data.
Recent disclosures said updated Phase 1b/2 TUPELO results showed REC-4881 delivered deeper and more durable reductions in polyp burden in familial adenomatous polyposis, with activity across the GI tract and a relatively clean safety profile that supports advancing toward a registrational study. Separately, the company reported quarterly revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments